OBIO Valuation

Orchestra Biomed Holdings Inc

Add to Watchlist

Advanced Chart

2.740

-0.010(-0.360%)

Overview
Forecast
Valuation

OBIO Relative Valuation

OBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OBIO is overvalued; if below, it's undervalued.

Historical Valuation

Orchestra Biomed Holdings Inc (OBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 37.86 is considered Fairly compared with the five-year average of 57.48. The fair price of Orchestra Biomed Holdings Inc (OBIO) is between 0.41 to 6.51 according to relative valuation methord.

Relative Value

Fair Zone

0.41-6.51

Current Price：2.74

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

3.18

P/B

Median3y

2.85

Median5y

1.83

-48.26

FCF Yield

Median3y

-19.60

Median5y

-19.60

Competitors Valuation Multiple

The average P/S ratio for OBIO's competitors is 7.92, providing a benchmark for relative valuation. Orchestra Biomed Holdings Inc Corp (OBIO) exhibits a P/S ratio of 37.86, which is 378.21% above the industry average. Given its robust revenue growth of -3.44%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

OBIO.O

Orchestra Biomed Holdings Inc

37.86

Average P/S: 7.92

-3.44%